Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiarrhythmia agents in heart failure]

P Duc1

  • 1Service de cardiologie, CHU Bichat Claude-Bernard, Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|April 1, 1995
PubMed
Summary

Supraventricular and ventricular arrhythmias are common in heart failure. Treatment for ventricular arrhythmias depends on ejection fraction, but caution is advised for asymptomatic cases due to potential dangers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A cardiac tumor].

La Revue de medecine interne·2007
Same author

[Heart insufficiency in the elderly].

Annales de cardiologie et d'angeiologie·2003
Same author

[Ambulatory management of chronic cardiac failure. Possible value of health networking].

Archives des maladies du coeur et des vaisseaux·2001
Same author

Synthesis and secretion of atrial natriuretic factor during chronic hypoxia: a study in the conscious instrumented rat.

Clinical science (London, England : 1979)·1990
Same author

Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure.

The Journal of clinical investigation·1990
Same author

[Percutaneous femoral artery coronary arteriography. 300 consecutive cases with French 5 catheters].

Archives des maladies du coeur et des vaisseaux·1988

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Supraventricular and ventricular arrhythmias frequently occur in patients with cardiac failure.
  • Current antiarrhythmic agents have not demonstrated improved survival in atrial fibrillation with left ventricular systolic dysfunction.

Purpose of the Study:

  • To outline treatment strategies for supraventricular and ventricular arrhythmias in cardiac failure.
  • To emphasize the importance of ejection fraction in guiding ventricular arrhythmia treatment.
  • To highlight the risks associated with antiarrhythmic drug use in asymptomatic ventricular arrhythmias.

Main Methods:

  • Review of current treatment guidelines for arrhythmias in cardiac failure.
  • Analysis of the role of ejection fraction in determining antiarrhythmic drug selection.
  • Evaluation of evidence supporting the use of antiarrhythmic drugs in asymptomatic ventricular arrhythmias.

Main Results:

  • Treatment for symptomatic ventricular tachycardia/fibrillation is stratified by ejection fraction (EF): low EF (amiodarone), intermediate EF (amiodarone and/or beta-blocker), normal EF (ventricular agents).
  • No antiarrhythmic drug has proven beneficial for survival in atrial fibrillation with left ventricular systolic dysfunction.
  • Restrictive use of antiarrhythmic drugs is recommended for asymptomatic ventricular arrhythmias due to limited benefits and significant pro-arrhythmic risks.
  • No medication is established as effective for ventricular tachycardia in hypertrophic cardiomyopathy.

Conclusions:

  • Antiarrhythmic drug selection for ventricular arrhythmias in cardiac failure should be guided by ejection fraction.
  • The use of antiarrhythmic drugs in asymptomatic ventricular arrhythmias should be approached with extreme caution.
  • Further research is needed to establish effective and safe treatments for specific arrhythmias in cardiac failure, particularly in hypertrophic cardiomyopathy.

Related Experiment Videos